De Novo and Secondary Myelodysplastic Syndrome
Standard treatment options:
- Myeloablative allogeneic stem cell transplantation.
- Erythropoeitic growth factors, in patients with endogenous erythropoietin levels less than 500 u/mL.
- 5-azacitidine or decitabine.
- Lenalidomide for patients with deletions of chromosome 5q31.
- Antithymocyte globulin.
Treatment options under clinical evaluation:
General Information About Pheochromocytoma and Paraganglioma
Pheochromocytomas and extra-adrenal paragangliomas are rare tumors arising from neural crest tissue that develops into sympathetic and parasympathetic paraganglia throughout the body. Sympathetic paraganglia include the following: The adrenal medulla. The organ of Zuckerkandl near the aortic bifurcation. Other paraganglia along the distribution of the sympathetic nervous system. Parasympathetic paraganglia include the following: The carotid body. Other paraganglia along the...
Read the General Information About Pheochromocytoma and Paraganglioma article > >
- Nonmyeloablative stem cell transplantation.
- Farnesyl transferase inhibitors (tipifarnib and lonafarnib).
- Combination regimens.
- Thrombopoietic agents.
Current Clinical Trials
Check for U.S. clinical trials from NCI's list of cancer clinical trials that are now accepting patients with de novo myelodysplastic syndromes and secondary myelodysplastic syndromes. The list of clinical trials can be further narrowed by location, drug, intervention, and other criteria.
General information about clinical trials is also available from the NCI Web site.
WebMD Public Information from the National Cancer Institute
Today in Cancer
WebMD Special Sections
Health Solutions From Our Sponsors
©2005-2013 WebMD, LLC. All rights reserved.
WebMD does not provide medical advice, diagnosis or treatment. See additional information.